RU2719194C2 - Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов - Google Patents

Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов Download PDF

Info

Publication number
RU2719194C2
RU2719194C2 RU2014106026A RU2014106026A RU2719194C2 RU 2719194 C2 RU2719194 C2 RU 2719194C2 RU 2014106026 A RU2014106026 A RU 2014106026A RU 2014106026 A RU2014106026 A RU 2014106026A RU 2719194 C2 RU2719194 C2 RU 2719194C2
Authority
RU
Russia
Prior art keywords
pathway
target genes
activity
target
subject
Prior art date
Application number
RU2014106026A
Other languages
English (en)
Russian (ru)
Other versions
RU2014106026A (ru
Inventor
Вильхельмус Франсискус Йоханнес ВЕРХАГ
ДЕ СТОЛЬПЕ Аня ВАН
ОЙЕН Хендрик Ян ВАН
Кальяна Чакравартхи ДУЛЛА
ДЕ ИНДА Марсия АЛВЕС
Ральф ХОФФМАНН
Original Assignee
Конинклейке Филипс Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Конинклейке Филипс Н.В. filed Critical Конинклейке Филипс Н.В.
Publication of RU2014106026A publication Critical patent/RU2014106026A/ru
Application granted granted Critical
Publication of RU2719194C2 publication Critical patent/RU2719194C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N5/00—Computing arrangements using knowledge-based models
    • G06N5/04—Inference or reasoning models
    • G06N5/048—Fuzzy inferencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Software Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Evolutionary Computation (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioethics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Pathology (AREA)
  • Probability & Statistics with Applications (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Mathematical Physics (AREA)
RU2014106026A 2011-07-19 2012-07-19 Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов RU2719194C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161509137P 2011-07-19 2011-07-19
US61/509,137 2011-07-19
EP11178148A EP2549399A1 (en) 2011-07-19 2011-08-19 Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
EP11178148.0 2011-08-19
PCT/IB2012/053686 WO2013011479A2 (en) 2011-07-19 2012-07-19 Assessment of cellular signaling pathway activity using probabilistic modeling of target gene expression

Publications (2)

Publication Number Publication Date
RU2014106026A RU2014106026A (ru) 2015-08-27
RU2719194C2 true RU2719194C2 (ru) 2020-04-17

Family

ID=44582424

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014106026A RU2719194C2 (ru) 2011-07-19 2012-07-19 Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов

Country Status (12)

Country Link
US (2) US11443831B2 (enExample)
EP (6) EP2549399A1 (enExample)
JP (3) JP6204354B2 (enExample)
KR (1) KR102064004B1 (enExample)
CN (2) CN109852671A (enExample)
BR (1) BR112014000965B8 (enExample)
DK (3) DK3418396T3 (enExample)
ES (3) ES2617195T3 (enExample)
IN (1) IN2014CN00675A (enExample)
MX (1) MX352827B (enExample)
RU (1) RU2719194C2 (enExample)
WO (1) WO2013011479A2 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
RU2017120287A (ru) 2012-02-28 2018-11-15 АйАрЭм ЭлЭлСи ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
JP6449779B2 (ja) 2012-12-26 2019-01-09 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価
TWI582239B (zh) * 2013-03-11 2017-05-11 諾華公司 與ｗｎｔ抑制劑相關之標記
EP3372695B1 (en) 2013-04-26 2020-09-09 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CN110444289A (zh) * 2013-06-28 2019-11-12 南托米克斯有限责任公司 用于诊断检测的识别的途径分析
JP2017502983A (ja) * 2013-10-02 2017-01-26 スリ テクノロジーズ エルティーディー． 不均一な腫瘍を処置するための患者特異的免疫療法
DK3013986T3 (en) 2014-01-03 2017-02-27 Koninklijke Philips Nv ASSESSMENT OF PI3K CELL SIGNALING ACTIVITY ACTIVITIES USING MATHEMATICAL MODELING OF TARGET EXPRESSION
US9838847B2 (en) 2014-09-11 2017-12-05 Google LLP Data driven evaluation and rejection of trained Gaussian process-based wireless mean and standard deviation models
US9810762B2 (en) * 2014-09-11 2017-11-07 Google Inc. Calculating mean wireless signal strengths using a gaussian process approach incorporating predictive standard deviations
US9880257B2 (en) * 2014-09-11 2018-01-30 Google Llc Gaussian process-based approach for identifying correlation between wireless signals
JP6730983B2 (ja) 2014-09-19 2020-07-29 ザ プロボスト，フェローズ，ファウンデーション スカラーズ，アンド ジ アザー メンバーズ オブ ボード，オブ ザ カレッジ オブ ザ ホーリー アンド アンディブ．トリニティー オブ クイーン エリザベス，ニアー ダブリン 癌の再発リスクを予測する方法
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN107077536B (zh) * 2014-10-24 2021-09-28 皇家飞利浦有限公司 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性
WO2016062892A1 (en) * 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) * 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CN105760707B (zh) * 2014-12-18 2018-07-31 中国科学院大连化学物理研究所 细胞基因翻译过程建模方法
JP7028763B2 (ja) * 2015-08-14 2022-03-02 コーニンクレッカ フィリップス エヌ ヴェ 標的遺伝子発現の数学的モデリングを使用するＮＦｋＢ細胞シグナリング経路活性の評価
EP3341875A1 (en) * 2015-08-27 2018-07-04 Koninklijke Philips N.V. An integrated method and system for identifying functional patient-specific somatic aberations using multi-omic cancer profiles
CN106897578B (zh) * 2015-12-15 2020-02-14 中国科学院大连化学物理研究所 一种细胞基因翻译过程建模方法
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US20170329914A1 (en) * 2016-05-11 2017-11-16 International Business Machines Corporation Predicting Personalized Cancer Metastasis Routes, Biological Mediators of Metastasis and Metastasis Blocking Therapies
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US10621236B2 (en) * 2016-09-16 2020-04-14 At&T Intellectual Property I, L.P. Concept based querying of graph databases
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
WO2018089927A1 (en) * 2016-11-11 2018-05-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of instance-specific somatic genome alterations with functional impact
AU2017364218A1 (en) 2016-11-25 2019-07-11 Koninklijke Philips N.V. Method to distinguish tumor suppressive FOXO activity from oxidative stress
CN106755464A (zh) * 2017-01-11 2017-05-31 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
CN107184991B (zh) * 2017-05-03 2020-05-26 武汉爱博泰克生物科技有限公司 PRDM15基因序列在制备NF-κB抑制剂中的应用
CN107164508A (zh) * 2017-06-16 2017-09-15 上海易毕恩基因科技有限公司 用于检测肝癌的基因标志物及其用途
EP3431582A1 (en) 2017-07-18 2019-01-23 Koninklijke Philips N.V. Cell culturing materials
CN107201411A (zh) * 2017-07-27 2017-09-26 上海市长宁区妇幼保健院 Mylk基因作为诊断子宫内膜癌的标志物
CN107385051A (zh) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法
EP3462348A1 (en) * 2017-09-28 2019-04-03 Koninklijke Philips N.V. Bayesian inference
CN111587293A (zh) 2017-10-02 2020-08-25 皇家飞利浦有限公司 确定免疫细胞类型和免疫应答的功能状态
EP3462349A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461916A1 (en) * 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
US11475995B2 (en) * 2018-05-07 2022-10-18 Perthera, Inc. Integration of multi-omic data into a single scoring model for input into a treatment recommendation ranking
CN108875009B (zh) * 2018-06-16 2021-10-22 上海豹云网络信息服务有限公司 一种用于对数据文件进行动态处理的方法及系统
US11354591B2 (en) 2018-10-11 2022-06-07 International Business Machines Corporation Identifying gene signatures and corresponding biological pathways based on an automatically curated genomic database
CN111670476B (zh) * 2018-12-21 2023-04-25 北京哲源科技有限责任公司 患病风险预测方法、电子设备及存储介质
US20220076785A1 (en) * 2018-12-21 2022-03-10 Phil Rivers Technology, Ltd. Method for acquiring intracellular deterministic event, electronic device and storage medium
CN113785075A (zh) 2019-05-03 2021-12-10 皇家飞利浦有限公司 高级别浆液性卵巢癌的预后方法
EP3812474A1 (en) 2019-10-22 2021-04-28 Koninklijke Philips N.V. Methods of prognosis in high-grade serous ovarian cancer
EP3965800A4 (en) * 2019-05-08 2023-02-15 Cedars-Sinai Medical Center Therapeutically active cells and exosomes
EP3739588A1 (en) 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
US11367508B2 (en) 2019-08-16 2022-06-21 Tempus Labs, Inc. Systems and methods for detecting cellular pathway dysregulation in cancer specimens
EP3822368A1 (en) 2019-11-14 2021-05-19 Koninklijke Philips N.V. Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression
EP3835433A1 (en) 2019-12-12 2021-06-16 Koninklijke Philips N.V. Notch signaling pathway activity as prognostic marker in bladder cancer
CA3163492A1 (en) * 2019-12-12 2021-06-17 Tempus Labs, Inc. Real-world evidence of diagnostic testing and treatment patterns in u.s. breast cancer patients
CN111139300B (zh) * 2020-02-19 2021-08-17 伯克利南京医学研究有限责任公司 一组结肠癌预后相关基因的应用
EP3882363A1 (en) 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
EP3978628A1 (en) 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prognostic pathways for viral infections
EP4136261B1 (en) 2020-04-16 2025-04-02 InnoSIGN B.V. Prognostic pathways for viral infections
CN111739586B (zh) * 2020-06-17 2024-04-05 浙江大学 以87个基因作为生物标志物预测细胞增殖活性的模型
EP3940704A1 (en) 2020-07-14 2022-01-19 Koninklijke Philips N.V. Method for determining the differentiation state of a stem cell
EP3960875A1 (en) 2020-08-28 2022-03-02 Koninklijke Philips N.V. Pcr method and kit for determining pathway activity
EP3965119A1 (en) 2020-09-04 2022-03-09 Koninklijke Philips N.V. Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices
EP3974540A1 (en) 2020-09-25 2022-03-30 Koninklijke Philips N.V. Method for predicting immunotherapy resistance
EP4015651A1 (en) 2020-12-17 2022-06-22 Koninklijke Philips N.V. Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients
EP4039825A1 (en) 2021-02-09 2022-08-10 Koninklijke Philips N.V. Comparison and standardization of cell and tissue culture
CN117295824A (zh) 2021-03-11 2023-12-26 皇家飞利浦有限公司 用于高风险脓毒症患者的预后通路
CN113278700B (zh) * 2021-06-04 2022-08-09 浙江省肿瘤医院 一种用于乳腺癌分型及预后预测的引物组及试剂盒
EP4434034A1 (en) * 2021-11-15 2024-09-25 InnoSIGN B.V. Assessment of gr cellular signaling pathway activity using mathematical modelling of target gene expression
CN113963745A (zh) * 2021-12-07 2022-01-21 国际竹藤中心 一种构建植物发育分子调控网络的方法及其应用
EP4569139A1 (en) 2022-08-12 2025-06-18 InnoSIGN B.V. Prediction and monitoring of immunotherapy in cancer
CN116083590B (zh) * 2023-03-23 2024-03-22 雄安妙心医学检验有限公司 一种基因检测试剂盒及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022575A2 (en) * 2002-09-05 2004-03-18 Toolgen, Inc. Bioinformatics analysis of cellular effects of artificial transcription factors
US20070009923A1 (en) * 2005-01-24 2007-01-11 Massachusetts Institute Of Technology Use of bayesian networks for modeling cell signaling systems
WO2007136787A2 (en) * 2006-05-17 2007-11-29 The Trustees Of Boston University Method to determine transcriptional regulation pathways in organisms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566130B1 (en) * 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
EP1910564A1 (en) * 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070112630A1 (en) 2005-11-07 2007-05-17 Scanscout, Inc. Techniques for rendering advertisments with rich media
WO2008086182A2 (en) * 2007-01-04 2008-07-17 University Of Rochester Use of gene signatures to design novel cancer treatment regimens
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
US20120252689A1 (en) * 2011-04-01 2012-10-04 Zhong Wu Gene expression signature for wnt/b-catenin signaling pathway and use thereof
EP2705164A1 (en) * 2011-05-05 2014-03-12 Clinical Genomics Pty Ltd A method of diagnosing neoplasms
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022575A2 (en) * 2002-09-05 2004-03-18 Toolgen, Inc. Bioinformatics analysis of cellular effects of artificial transcription factors
US20070009923A1 (en) * 2005-01-24 2007-01-11 Massachusetts Institute Of Technology Use of bayesian networks for modeling cell signaling systems
WO2007136787A2 (en) * 2006-05-17 2007-11-29 The Trustees Of Boston University Method to determine transcriptional regulation pathways in organisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROGERS SIMON et al. "Bayesian model-based inference of transcription factor activity." BMC bioinformatics, 2007, 8(Suppl 2):S2; doi:10.1186/1471-2105-8-S2-S2. *

Also Published As

Publication number Publication date
EP2549399A1 (en) 2013-01-23
EP4130291B1 (en) 2024-01-10
JP6204354B2 (ja) 2017-09-27
EP4130291C0 (en) 2024-01-10
US20230105263A1 (en) 2023-04-06
EP3173489A1 (en) 2017-05-31
EP2734643A2 (en) 2014-05-28
US11443831B2 (en) 2022-09-13
KR102064004B1 (ko) 2020-01-08
DK2734643T3 (en) 2017-03-20
BR112014000965A2 (pt) 2017-06-13
DK3173489T3 (en) 2018-12-10
CN103649337B (zh) 2018-11-13
ES2874452T3 (es) 2021-11-05
CN109852671A (zh) 2019-06-07
EP4130291A1 (en) 2023-02-08
EP3173489B1 (en) 2018-09-19
JP6807430B2 (ja) 2021-01-06
JP2019129850A (ja) 2019-08-08
EP3418396B1 (en) 2021-03-24
JP6783729B2 (ja) 2020-11-11
EP3831957A1 (en) 2021-06-09
BR112014000965B1 (pt) 2021-08-24
JP2017205129A (ja) 2017-11-24
WO2013011479A3 (en) 2013-03-14
IN2014CN00675A (enExample) 2015-04-03
WO2013011479A2 (en) 2013-01-24
CN103649337A (zh) 2014-03-19
EP3418396A1 (en) 2018-12-26
BR112014000965B8 (pt) 2022-11-08
EP3831957B1 (en) 2022-09-07
MX2014000557A (es) 2014-05-01
ES2617195T3 (es) 2017-06-15
EP2734643B1 (en) 2016-12-07
KR20140046464A (ko) 2014-04-18
ES2700617T3 (es) 2019-02-18
MX352827B (es) 2017-12-11
DK3418396T3 (da) 2021-05-25
JP2014520566A (ja) 2014-08-25
RU2014106026A (ru) 2015-08-27
US20140156200A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
AU2022201153B2 (en) Methods and compositions for detecting esophageal neoplasias and/or metaplasias in the esophagus
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
KR101234281B1 (ko) 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제
KR101421326B1 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
WO2003042661A2 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
KR20120082906A (ko) 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
JP2003088388A (ja) 新規な全長ｃＤＮＡ
JP2003135075A (ja) 新規な全長ｃＤＮＡ
AU2016351889A1 (en) Detection of foetal chromosomal aneuploidies using DNA regions that are differentially methylated between the foetus and the pregnant female
AU2016331663A1 (en) Pathogen biomarkers and uses therefor
KR20220024184A (ko) 대장암의 검출
CN101573453A (zh) 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法
MXPA05005653A (es) Determinacion y seleccion terapeutica de genes de insuficiencia cardiaca.
KR20220054401A (ko) 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
KR20220025749A (ko) 대장암의 검출
JP2003304888A (ja) 化合物の毒性予測のための方法
KR20040065524A (ko) 백혈병을 검사 및 치료하는 방법
CN114127314A (zh) 用于对乳腺癌的亚型(Subtype)进行鉴别或者分类的鉴别标志物遗传基因组、方法和套件
AU2016202635B2 (en) Method for assessing embryotoxicity
KR20060045950A (ko) 혈액학적 악성종양에 대한 예후
KR20160059446A (ko) 암 유전체 돌연변이 검출용 유전자 패널